For the Inventor, By the Inventor

Enter assignee name

Zug, Switzerland

Sucampo Ag

Calculating rank

USPTO Granted Patents = 59

% Expired Patents = 44.1

CIPO Patents = 9

EPO Patents = 27

Forward Citations = 353

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Ryuji Ueno (57 out of 151 patents)

Ryu Hirata (9 out of 13 patents)

Yasuhiro Harada (7 out of 8 patents)

4. Tatsuya Matsukawa (5 out of 14 patents)

5. Kazuhiro Masuzaki (4 out of 7 patents)

6. Tsuyoshi Habe (4 out of 5 patents)

7. John Cuppoletti (3 out of 13 patents)

8. Junichi Kawasaki (2 out of 2 patents)

9. Yoshie Nishimura (2 out of 2 patents)

10. Yukiko Hashitera (2 out of 3 patents)

11. Myra L Patchen (2 out of 2 patents)

12. Sachiko Kuno (2 out of 8 patents)

13. Robert Gurny (1 out of 21 patents)

14. Michael Möller (1 out of 3 patents)

15. Noriyuki Yamamoto (1 out of 2 patents)

Core Competencies:

Pharmaceutical Composition

Prostaglandin Analog

Gastrointestinal Disorders

Ocular Hypertension

Soft-Gelatin Capsule

Stem Cell Growth

Chloride Channel Opener

Apoptosis Inhibitor

Macrolide Compounds

Fatty Acid Derivative

Anti-Constipation

Tumor Treatment

59 patents: Sort by Forward Citations

1. 11534404 - Multilayer beads for pharmaceutical use (2022-12-27),

2. 10561649 - Pharmaceutical combination of opioid and prostaglandin compound (2020-02-18),

3. 9254326 - Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound (2016-02-09),

4. 9242950 - Method for preparing a fatty acid derivative (2016-01-26),

5. 9084815 - Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor (2015-07-21),

6. 8969324 - Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound (2015-03-03),

7. 8962688 - Method for the treatment of gastrointestinal disorders (2015-02-24),

8. 8889735 - Method for treating asthenopia (2014-11-18),

9. 8871752 - Method for modulating stem cell growth (2014-10-28),

10. 8853268 - Ophthalmic solution (2014-10-07),

11. 8835571 - Fatty acid derivative-polymer conjugate (2014-09-16),

12. 8748481 - Method for treating gastrointestinal disorder (2014-06-10),

13. 8748454 - Anti-constipation composition (2014-06-10),

14. 8669284 - Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound (2014-03-11),

15. 8609729 - Method for treating macular degeneration (2013-12-17),

Company Overview

Sucampo AG, headquartered in Zug, Switzerland, specializes in the development and manufacturing of pharmaceutical compositions. The company focuses on innovative therapies targeting gastrointestinal disorders and ocular hypertension, leveraging core technologies such as prostaglandin analogs and soft-gelatin capsules. Sucampo's research extends into areas like stem cell growth and apoptosis inhibition, positioning it at the forefront of pharmaceutical advancements aimed at improving patient outcomes in various therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

59 Patents

#18 in Zug

#259 in Switzerland

#12,252 in the World

Zug, Switzerland

Sucampo Ag

Forward Citations = 353

26 inventors:

Ryuji Ueno (57 out of 151 patents)

Ryu Hirata (9 out of 13 patents)

Yasuhiro Harada (7 out of 8 patents)

4. Tatsuya Matsukawa (5 out of 14 patents)

5. Kazuhiro Masuzaki (4 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sucampo Ag. Retrieved from https://idiyas.com/company/sucampo-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…